First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 7786-7798
DOI: 10.1007/s00259-026-08158-w ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 02.10.2026. Verfasst von Kadir Gultekin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. Hauptthemen laut MEDLINE: Leukocytes, Oxyquinoline, Positron Emission Tomography Computed Tomography, Radioisotopes. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Myalgic Encephalomyelitis Research UK (MERUK), University of Alabama Health Services Foundation.
Abstract (Originalsprache)
Purpose
Cell tracking with zirconium-89 PET has the potential for widespread clinical and research applications, including imaging infection and inflammation and tracking cell-based therapies. This prospective first-in-human clinical trial assessed the dosimetry and safety profile of [ 89 Zr]Zr-oxine-labeled autologous leukocytes in healthy female participants.
Methods
Four healthy adult female participants (ages 37–53) received 10.9 ± 2.9 MBq of [ 89 Zr]Zr-oxine-labeled autologous leukocytes and underwent whole-body PET/CT imaging at five time points (0, 4, 24, 48, and 72 h). Regions of interest were automatically segmented on CT using a machine learning-based approach and manually refined. Time-integrated activity coefficients were calculated using Simpson’s rule, with physical decay assumed beyond the final time point. Mean absorbed-dose and effective-dose coefficients were estimated using OLINDA 2.1.
Results
Administration was well-tolerated among all participants. The highest mean absorbed-dose coefficients (mGy/MBq) with standard deviation were observed in the spleen (3.52 ± 1.38), liver (2.1 ± 0.45), adrenals (1.62 ± 0.24), uterus (1.48 ± 0.98), and kidneys (1.36 ± 0.12). The mean effective-dose coefficient was 0.92 ± 0.06 mSv/MBq, numerically lower than the predicted value of 1.14 mSv/MBq based on the distribution of [ 111 In]In-oxine-labeled leukocytes in adult females ( P = 0.006, one-sample t-test). The use of [ 89 Zr]Zr-oxine-labeled leukocytes enabled the visualization of leukocyte distribution and temporal dynamics.
Conclusion
This study demonstrates the safety and favorable dosimetry of [ 89 Zr]Zr-oxine-labeled leukocytes in healthy humans. These results support the further use of this approach for imaging autologous leukocytes using PET in a range of clinical and research settings.
Trial registration
ClinicalTrials.gov NCT03807973. Registered January 16, 2019.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
- Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. mcconatj@mcmaster.ca.
Förderung
- Myalgic Encephalomyelitis Research UK (MERUK)
- University of Alabama Health Services Foundation
Zitieren
APA
Gultekin, K., Bartels, J. L., Cardenas, C. E., Kumar, Y., Gimblet, G. R., Jones, C. L., Bankston, C., Jeffers, C. D., White, S. L., Lapi, S. E., Younger, J. W., & McConathy, J. E. (2026). First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 7786-7798. https://doi.org/10.1007/s00259-026-08158-w
Vancouver
Gultekin K, Bartels JL, Cardenas CE, Kumar Y, Gimblet GR, Jones CL, et al. First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):7786-7798. doi:10.1007/s00259-026-08158-w
BibTeX
@article{Gultekin2026,
author = {Gultekin, Kadir and Bartels, Jennifer L and Cardenas, Carlos E and Kumar, Yogesh and Gimblet, Grayson R and Jones, Chloe L and Bankston, Christina and Jeffers, Charlotte D and White, Sharon L and Lapi, Suzanne E and Younger, Jarred W and McConathy, Jonathan E},
title = {First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {7786--7798},
doi = {10.1007/s00259-026-08158-w}
}
EUVIMED